deltatrials
Completed PHASE3 NCT00078325

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

Sponsor: Cephalon

Conditions Hypopnea Obstructive Sleep Apnea
Interventions Armodafinil 150 mg/day Armodafinil 250 mg/day Placebo
Updated 6 times since 2017 Last updated: Jul 12, 2013 Started: Feb 29, 2004 Primary completion: Nov 30, 2004 Completion: Nov 30, 2004

A PHASE3 clinical study on Hypopnea and Obstructive Sleep Apnea, this trial is completed. The trial is conducted by Cephalon and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cephalon
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.